SCHEMBL3523461

SCHEMBL3523461

O=CCC1(c2ccccc2)CCN(C(=O)c2ccccc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 4/20 0.51
ALDH1A1 P00352 2/20 0.50
CHRM2 P08172 1/20 0.50
CHRM3 P20309 1/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.49
OPRD1 P41143 1/20 0.48
OPRK1 P41145 1/20 0.48
CRBN Q96SW2 1/20 0.47
BLM P54132 1/20 0.47
SIGMAR1 Q99720 1/20 0.46
RIPK1 Q13546 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
TP53 P04637 1/20 0.46
KCNH2 Q12809 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3527130 0.87 HSD11B1 (0.42) CCR5LMNA
SCHEMBL8129263 0.84 CHRM2 (0.48) ALDH1A1CHRM2CHRM3LMNACRBN
SCHEMBL2702148 0.82 MAOA (0.56) CCR5ALDH1A1CHRM2CHRM3LMNA
SCHEMBL6947952 0.79 TACR2 (0.61) CCR5
SCHEMBL19207570 0.78 MAOA (0.54) LMNA
SCHEMBL3272198 0.78 TACR1 (0.58) CCR5CHRM2CHRM3OPRD1OPRK1
SCHEMBL38352 0.77 HPGDS (0.59) CCR5ALDH1A1LMNAOPRD1OPRK1
SCHEMBL8143466 0.77 EPHX2 (0.50) ALDH1A1CHRM2CHRM3LMNAHPGD
SCHEMBL8143470 0.77 EPHX2 (0.50) ALDH1A1CHRM2CHRM3LMNAHPGD
SCHEMBL6998425 0.76 EPHX2 (0.53) CCR5ALDH1A1CHRM2CHRM3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-7645771-B2 CCR5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORP. (US) 2010-01-12 US disclosed
US-20060229336-A1 Ccr5 antagonists as therapeutic agents SMITHKLINE BEECHAM CORPORATION 2006-10-12 US disclosed
CN-1744899-A Piperidine derivatives as CCR5 antagonists SMITHKLINE BEECHAM CORP (US) 2006-03-08 CN disclosed
EP-1569646-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004054974-A2 PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229336-A1 Ccr5 antagonists as therapeutic agents CCR5, CCR1, CXCR3 CCR5 1/4885ALDH1A1 2787/4885CHRM2 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.